Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

In Silico Exploration of the Trypanothione Reductase (TryR) of L. mexicana.

Created on 26 Jun 2026

Authors

Francisco J Barrera-Téllez, Fernando D Prieto-Martínez, Alicia Hernández-Campos, Karina Martínez-Mayorga, Rafael Castillo-Bocanegra

Published in

International journal of molecular sciences. Volume 24. Issue 22. Nov 07, 2023. Epub Nov 07, 2023.

Abstract

Human leishmaniasis is a neglected tropical disease which affects nearly 1.5 million people every year, with Mexico being an important endemic region. One of the major defense mechanisms of these parasites is based in the polyamine metabolic pathway, as it provides the necessary compounds for its survival. Among the enzymes in this route, trypanothione reductase (TryR), an oxidoreductase enzyme, is crucial for the Leishmania genus' survival against oxidative stress. Thus, it poses as an attractive drug target, yet due to the size and features of its catalytic pocket, modeling techniques such as molecular docking focusing on that region is not convenient. Herein, we present a computational study using several structure-based approaches to assess the druggability of TryR from L. mexicana, the predominant Leishmania species in Mexico, beyond its catalytic site. Using this consensus methodology, three relevant pockets were found, of which the one we call σ-site promises to be the most favorable one. These findings may help the design of new drugs of trypanothione-related diseases.

PMID:
38003236
Bibliographic data and abstract were imported from PubMed on 26 Jun 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 8
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement